-- 加拿大皇家银行资本市场（RBC Capital Markets）周四在一份报告中指出，Utz Brands (UTZ) 的季度至今趋势看似疲软，但其潜在增长依然稳健，主要得益于分销渠道的拓展、创新以及加州市场的扩张势头。 报告称，管理层对公司新产品将支撑营收增长持乐观态度，并且公司在燃油、农产品和货运方面拥有充足的资金保障，足以应对今年大部分时间的通胀担忧。 分析师表示，鉴于第一季度市场波动较大以及消费者环境的变化，公司对咸味零食品类的全年业绩预期仍维持在基本持平的水平。 鉴于第一季度业绩基本符合预期并重申了业绩预期，该券商表示将调整其2026年的业绩预测，预计有机销售额增长2.5%，EBITDA增长6%，每股收益下降4.1%。 加拿大皇家银行资本市场维持对该股的“跑赢大盘”评级，目标价为15美元。 Utz Brands的股价在周四的交易中下跌了5%。
Price: $7.88, Change: $-0.42, Percent Change: -5.06%
Consumer stocks were edging down late Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) each decreasing 0.1%.In corporate news, Tapestry (TPR) raised its fiscal 2026 outlook after delivering a Q3 beat, but provided a subdued Q4 sales guidance for its Kate Spade brand. Its shares dropped more than 13%.Shake Shack (SHAK) shares slumped 28% after the company's Q1 results missed Wall Street estimates.Planet Fitness (PLNT) shares tumbled 32% after the company tempered its full-year outlook amid fewer-than-expected member additions in Q1.McDonald's (MCD) reported better-than-expected Q1 results as comparable sales rebounded more than market estimates despite what the company described as a "challenging" environment. Its shares rose 0.3%.
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.2%.In corporate news, Entrada Therapeutics (TRDA) shares tumbled 57% after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5.5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.
Price: $10.72, Change: $-0.23, Percent Change: -2.10%